The changing impact of cytomegalovirus among hematopoietic cell transplant recipients during the past decade: A single institutional cohort study

Background With advancements in allogeneic hematopoietic cell transplantation (alloHCT), the need for cytomegalovirus (CMV) surveillance persists. Methods We present a retrospective analysis on the impact of CMV with preemptive therapy in 1065 alloHCT patients with donor and/or recipient CMV seropos...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2022-06, Vol.24 (3), p.e13825-n/a
Main Authors: Johnsrud, Joyce J., Nguyen, Isabelle T., Domingo, Walter, Raval, Amit D., Tang, Yuexin, Narasimhan, Balasubramanian, Efron, Bradley, Brown, Janice (Wes)
Format: Article
Language:English
Subjects:
Antiviral drugs
Blood transfusion
CMV
Cohort analysis
Confidence intervals
Cytomegalovirus
Erythrocytes
Globulins
hematopoietic cell transplant
Impact analysis
letermovir
Multivariate analysis
Neutropenia
Patients
Preempting
Prophylaxis
Stem cell transplantation
Toxicity
Transplantation
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background With advancements in allogeneic hematopoietic cell transplantation (alloHCT), the need for cytomegalovirus (CMV) surveillance persists. Methods We present a retrospective analysis on the impact of CMV with preemptive therapy in 1065 alloHCT patients with donor and/or recipient CMV seropositivity from 2009 to 2019. Results Fifty‐one percent developed clinically significant CMV infection (CMV‐CSI); 6.5% had CMV disease. In multivariate analysis stratified by serostatus and preparative regimen, the use of anti‐thymocyte globulin (hazard ratios 2.97, 95% confidence interval 2.00–4.42, p 
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.13825